Background Guidelines recommend risk-adjusted management of pulmonary embolism
(PE). We investigated whether treatment of acute intermediate-risk PE with parenteral …

Background Current guidelines recommend a risk-adjusted treatment strategy for the
management of acute pulmonary embolism. This is a particular patient category for whom …

Patients with intermediate-risk pulmonary embolism (PE) may, depending on the method
and cut-off values used for definition, account for up to 60% of all patients with PE and have …

We would like to thank H. Slabbynck and co-workers for their interest in the 2019 European
Society of Cardiology/European Respiratory Society guidelines on the diagnosis and …

Background Patients with intermediate-high-risk pulmonary embolism (PE) who have both
right ventricular dysfunction and elevated cardiac biomarkers are at a high risk of early …

Introduction Availability of new treatment strategies for patients with acute pulmonary
embolism (PE) have changed clinical practice with potential influence in short-term patients' …

Introduction Intermediate-high risk pulmonary embolism (IHR-PE) has a poor prognosis, but
is under-represented in trials of direct oral anticoagulants (DOACs) in venous …

Objectives The safety and efficacy of direct oral anticoagulants (DOACs) in intermediate-
high risk pulmonary embolism (PE) are unknown. The aims of the present study were to …

Background Evidence-based clinical practice guidelines define initial management of acute
pulmonary embolism (PE) according to risk stratification for early death. Aims The aims of …

Stavros Konstantinides: Risk-adjusted treatment of PE has indeed been the focus of our
research for more than three decades, and in the 2019 ESC Guidelines we put a lot of effort …